All stock lists
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)
GB · Delayed Price · Currency is USD
Healthcare · Medical - Pharmaceuticals
71.75-4.98 (-6.50%)
Insider Score
––Not scored
KNSA Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
KNSA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 243.60 M | 214.27 M | 202.13 M | 180.85 M | 156.80 M | 137.78 M |
| Revenue Growth (YoY) | 55.36 % | 55.51 % | 64.95 % | 61.17 % | 44.34 % | 72.54 % |
| Cost of Revenue | 111.64 M | 96.37 M | 91.10 M | 83.59 M | 71.02 M | 61.66 M |
| Gross Profit | 131.96 M | 117.89 M | 111.03 M | 97.26 M | 85.76 M | 76.13 M |
| SG&A Expense | 63.87 M | 61.15 M | 56.77 M | 49.10 M | 46.86 M | 43.53 M |
| R&D Expense | 40.90 M | 27.48 M | 34.64 M | 24.14 M | 18.75 M | 19.32 M |
| Operating Expenses | 104.77 M | 88.63 M | 91.26 M | 73.24 M | 65.62 M | 62.85 M |
| Operating Income | 27.19 M | 29.27 M | 19.77 M | 24.02 M | 20.16 M | 13.27 M |
| Pretax Income | 31.14 M | 32.68 M | 23.27 M | 27.16 M | 22.88 M | 15.56 M |
| Tax Provision | 5.71 M | 10.09 M | 9.07 M | 8.72 M | 5.04 M | 7.03 M |
| Net Income | 25.43 M | 22.59 M | 14.20 M | 18.43 M | 17.83 M | 8.54 M |
| EPS (Basic) | 0.33 | 0.30 | 0.19 | 0.25 | 0.24 | 0.12 |
| EPS (Diluted) | 0.30 | 0.27 | 0.18 | 0.23 | 0.23 | 0.11 |
| Shares Outstanding | 77.58 M | 76.52 M | 74.20 M | 73.61 M | 73.44 M | 72.65 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.